Wheatley MedTech Partners
2
7M
2
1
- Stages of investment
- Areas of investment
Summary
The top amount of exits for fund were in 2013. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2012. Deals in the range of 5 - 10 millions dollars are the general things for fund.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care. Among the most popular portfolio startups of the fund, we may highlight Oligomerix, Enanta Pharmaceuticals.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Wheatley MedTech Partners, startups are often financed by Techno Venture Management, Oxford Bioscience Partners, Advent International. The meaningful sponsors for the fund in investment in the same round are Yasuda Enterprise Development, Wheatley Partners, Techno Venture Management. In the next rounds fund is usually obtained by Thuja Capital, Techno Venture Management, Oxford Bioscience Partners.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Biotechnology (2)
- Pharmaceutical (1)
- Health Care (1)
- Medical (1)
- Ediscovery (1)
- Investments by region
-
- United States (2)
- Peak activity year
- 2004
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Oligomerix | 23 Apr 2012 | Biotechnology, Medical, Ediscovery | Early Stage Venture | 2M | United States, New York |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.